Next Article in Journal
Use of Ceftaroline in Hospitalized Patients with and without COVID-19: A Descriptive Cross-Sectional Study
Previous Article in Journal
HPLC-PDA-ESI-MS/MS Profiling and Anti-Biofilm Potential of Eucalyptussideroxylon Flowers
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 10
Issue 7
10.3390/antibiotics10070762
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment

by
María Jesús Serrano
1,
Diego García-Gonzalo
1,
Eunate Abilleira
2,
Janire Elorduy
2,
Olga Mitjana
1,
María Victoria Falceto
1,
Alicia Laborda
1,
Cristina Bonastre
1,
Luis Mata
3,
Santiago Condón
1 and
Rafael Pagán
1,*
1
Instituto Agroalimentario de Aragón-IA2, Universidad de Zaragoza-CITA, 50013 Zaragoza, Spain
2
Public Health Laboratory, Office of Public Health and Addictions, Ministry of Health of the Basque Government, 48160 Derio, Spain
3
Department of R&D, ZEULAB S.L., 50197 Zaragoza, Spain
*
Author to whom correspondence should be addressed.
Antibiotics 2021, 10(7), 762; https://doi.org/10.3390/antibiotics10070762
Submission received: 3 June 2021 / Revised: 15 June 2021 / Accepted: 21 June 2021 / Published: 23 June 2021
(This article belongs to the Section Antibiotics Use and Antimicrobial Stewardship)
Browse Figures
Versions Notes

Abstract

:
Many of the infectious diseases that affect livestock have bacteria as etiological agents. Thus, therapy is based on antimicrobials that leave the animal’s tissues mainly via urine, reaching the environment through slurry and waste water. Once there, antimicrobial residues may lead to antibacterial resistance as well as toxicity for plants, animals, or humans. Hence, the objective was to describe the rate of antimicrobial excretion in urine in order to select the most appropriate molecule while reducing harmful effects. Thus, 62 pigs were treated with sulfamethoxypyridazine, oxytetracycline, and enrofloxacin. Urine was collected through the withdrawal period and analysed via LC-MS/MS. Oxytetracycline had the slowest rate of degradation (a half-life time of 4.18 days) and the most extended elimination period in urine (over 2 months), followed by enrofloxacin (a half-life time of 1.48 days, total urine elimination in ca. 3 weeks) and sulfamethoxypyridazine (a half-life time of 0.49 days, total urine elimination in ca. 1 week). Bacterial sensitivity and recommendations for responsible use are limiting when selecting the treatment. Nevertheless, with similar effectiveness, sulfamethoxypyridazine would be the choice, as waste treatment would only need to be implemented for 1 week after treatment. Thus, more in-depth knowledge regarding antibacterial elimination would improve resource management, while protecting animals and consumers’ health.

1. Introduction

Antimicrobials are compounds administered to livestock for a number of reasons. On the one hand, they have traditionally been administered for non-therapeutic purposes, including disease prophylaxis and growth promotion [1,2]; on the other hand, they can be dispensed to treat diseases when they emerge. The diversity of uses for antimicrobials in farm breeding has led to an increased worldwide demand for antibiotics in livestock production which has even surpassed the total amount of human consumption [3]. As a consequence, it is now encouraged to rationalize their use [4,5]. Furthermore, the EMA (European Medicines Agency) has issued recommendations regarding their order of eligibility [6]. Indeed, growth promoters have been banned in the European Union since 2006, and prophylaxis is now likewise restricted in some animal groups (Regulation (EU) 2019/4 [7] and Regulation (EU) 2019/6 [8]). Nevertheless, the severity of some illnesses still requires treatment with antimicrobials.
Ideally, disease management would involve an accurate diagnosis of the causal agent involved, through the collection of an accurate sample for bacterial culture and antimicrobial susceptibility testing. Nonetheless, susceptibility is not the only feature to be considered, as certain antimicrobials are limited to human use [6], and the mode of administration of certain other antimicrobials might not be feasible on each type of farm. After administration, antimicrobials spread throughout the animal’s organism, reaching most of its tissues. Nevertheless, the degree of concentration in each organ depends on the antibiotic’s pharmacokinetics as well as the moment of treatment. Once the compound has fulfilled its function, it leaves the tissues and is excreted through several pathways, of which urine is one of the most predominant [9,10,11,12,13].
Although antimicrobial therapy significantly reduces economic loss and mortality rates on farms, antimicrobial residues produce a considerable array of negative side effects when they are released to the environment. On the one hand, antimicrobial residues exert a series of potential long-term adverse effects on humans and animals [14,15,16,17]. On the other, such deposits wield an intense pressure towards the genetic selection of resistant bacteria [18,19]. Although direct damage on human health is the most visible consequence, the development of resistant bacteria populations is the most severe side effect, as antimicrobials become useless against common illnesses easily addressed before. So severe is this problem that, by the year 2050, antimicrobial resistance generation (AMR) is estimated to be causing 10 million deceases per year overpassing illnesses such as cancer [4].
Several studies have set out to determine the amount of antimicrobial residues in manure and slurry and have found concentrations as high as 20,000 µg kg−1 of sulfonamide in Switzerland [20], 43 µg kg−1 of tiamulin in Germany [21], and 31 different antibiotic residues in China, with concentrations of sulfamethazine exceeding 5650 µg kg−1 [22]. Manure and slurry are usually used as natural fertilizers in agriculture, thereby dramatically spreading antibacterial residues in nature [23,24]. They are washed from the soil by rainwater, with the possibility of reaching nearby streams [25,26,27]. The United States Geological Survey (USGS) recovered 21 different antibiotics from watercourses in 1999—2000 [28].
Once these compounds have reached the environment, it is no longer feasible to eliminate them because some of them are not biodegradable [29]. The best way to manage them is by their destruction before they leave the farm. Several methods are being studied to avoid antibiotic release, such as heating [30,31], sorption of antibiotics onto carbonaceous materials [18], anaerobic digestion [32,33], manure composting [34,35], solid-liquid separation [36], and Fenton reaction [37]. These procedures involve a series of technologies, the choice of which will be dependent on the antimicrobial used and the concentration excreted, which, in turn, will depend on the moment of therapy. Moreover, an antimicrobial will be chosen for its effectiveness and for its compliance with European recommendations. Hence, this study’s objective is to describe the rate of antimicrobial excretion in urine after treatment with a series of different antimicrobials (a tetracycline, a sulfonamide, and a quinolone) in order to suggest which is the most appropriate molecule for therapeutical treatment, thereby guaranteeing a successful therapy along with the most thorough elimination of antimicrobial residues, to ensure sustainable resource management.

2. Results and Discussion

Antibacterial therapy is widespread and goes hand in hand with our current welfare state and economic development. Once antibiotics exert their effect, urine has been demonstrated to be the main path of elimination of most of their residues. Unexpected delivery of these compounds to external areas such as farm surroundings or the food chain [21] might exacerbate the serious problem of the emergence of AMR. One of the easiest ways of limiting the entrance of antibacterial compounds into the environment is by treating animal wastes before their removal from farm facilities [38]. Thus, better knowledge on the subject of antimicrobial elimination would rationalize production thanks to better resource management in waste treatment and by helping producers to choose the most suitable antibacterial treatment. A detailed study of the excretion rates of antimicrobials via urine would represent a first step in helping to make the best decisions when planning waste management. Thus, as a first step, 62 pigs were treated with several antimicrobials currently used in livestock farming (sulfamethoxypyridazine, oxytetracycline, and enrofloxacin). After collection, urine samples were analysed using LC-MS/MS within the first month, as certain antimicrobials might otherwise soon have degraded [39,40]. Novel extraction procedures and analysis techniques were developed in order to perform accurate analysis.

2.1. Excretion of Sulfamethoxypyridazine via Urine

Sulfamethoxypyridazine is a bacteriostatic compound from the sulfonamide family which, once administrated, spreads widely throughout the body. After attaining therapeutic concentrations in the bloodstream and having reached body tissues, it is mainly excreted through the kidneys, although it can be excreted to a lesser extent via fluids other than urine [41]. It can be classified as a long-acting sulfonamide, which is why the withdrawal period of sulfamethoxypyridazine-based drugs for food-producing animals is quite extended (Table 1).
Figure 1 shows the occurrence of sulfamethoxypyridazine concentration in urine through the withdrawal period. As expected, this compound was present in higher concentrations within the first days, decreasing at an exponential rate as the withdrawal period progressed until reaching concentrations that approached the LoD of the chromatographic technique. The decrease of sulfamethoxypyridazine in urine to levels as low as the LoD (10 ppb) ensures almost complete excretion. From these data, and according to Equation (1), this is equivalent to a half-life time of 0.49 days (Table 1).
Figure 1 also displays somewhat wide variations among the elimination rates in individual animal specimens. Although this variability between animals subjected to the same treatment and withdrawal period could be viewed as large (as reflected in the R2 values of the regression (Table 1)), differences between rates of removal are ascribable to individual variations. These pharmacokinetic differences are also consistent with the ones previously described for other antimicrobials such as macrolides [42] or even for sulfonamide pharmacokinetics after treatment via either oral [43] or intravenous administration [44].
According to the regression carried out, the time period required to complete the excretion of sulfamethoxypyridazine by urine could be estimated at almost a week (Table 1). Although sulfamethoxypyridazine is rapidly eliminated, this antimicrobial family is nevertheless commonly found in high levels in farm wastes [45], and thus, waste treatments are required for at least seven days after the end of treatment, and their features will be dependent on the concentration of the excreted sulfonamide.

2.2. Excretion of Oxytetracycline via Urine

Oxytetracycline is commonly administered via intramuscular injection and usually has long-lasting formulations: the drug is slowly released through the body over a prolonged period of time, and this behaviour is reflected in certain studies which detected long mean residence times [46], which correspond with the extended withdrawal period set by manufacturers for commercial oxytetracycline-based products (Table 1). Regarding its excretion pathways, 60% of the antibiotic administered in the treatment is excreted in urine via glomerular filtration, while the remaining 40% is eliminated in the faeces [9].
Figure 2 shows the occurrence of oxytetracycline concentration in urine through the withdrawal period. It shows that the antimicrobial concentration in urine decreased as the withdrawal period progressed, and the compound was depleted following an exponential rate. Once more, certain notable differences between the rates of excretion of oxytetracycline via urine in animals subjected to the same treatment and withdrawal period might be related to individual characteristics. Although certain variations in the concentrations can be observed, such differences in oxytetracycline pharmacokinetics have been previously described [47].
The half-life time calculated using Equation (1) for oxytetracycline in urine was 4.18 days (Equation (1), Table 1). Considering the compound’s high initial concentration, and extrapolating from the regression calculating the time required for the entire excretion of the antimicrobial from urine, more than two months would be needed to attain a complete excretion, a much longer period when compared to the end of the withdrawal period set by the manufacturer (28 days). This could be one of the reasons why this antimicrobial family is frequently detected at high levels in farm wastes [48], along with the fact that waste treatments are often either poor or non-existent. Tetracyclines have indeed been detected in groundwaters and lagoons in the vicinity of swine production facilities [49,50,51].

2.3. Excretion of Enrofloxacin via Urine

Enrofloxacin absorption is nearly complete after intramuscular administration, but to a great extent it is metabolized to ciprofloxacin. This is the reason why both compounds need to be explored via analysis. Enrofloxacin is mainly excreted via urine, with concentrations several times higher than in blood plasma; only slight amounts appear in faeces [10].
Enrofloxacin concentrations described in urine through the withdrawal period are presented in Figure 3. As with the other two antibacterial compounds, enrofloxacin concentrations declined as the withdrawal period progressed, and concentration decrease was an exponential function of time. From the regression over the data obtained, the compound’s half-life time was found to be 1.48 days (Table 1).
Apart from half-life times, Table 1 shows the regression’s goodness of fit. Once again, a low R2 value was found, as differences could be observed between the concentrations described in different animals subjected to the same treatment and withdrawal period. Nonetheless, such divergences have been previously demonstrated for other antimicrobials and drugs in general. In particular, differences in enrofloxacin metabolization have been previously described in plasma after oral [52] and subcutaneous [53] administration in pigs.
The regression also allowed us to estimate the time period after the end of treatment for the complete excretion of enrofloxacin: almost three weeks. As occurred with oxytetracycline, pigs would actually continue excreting enrofloxacin long after the end of the withdrawal period set by the manufacturer (12 days). This means that although antimicrobials might have been removed from muscle, they are still being disseminated by previously treated animals and should be taken into consideration in terms of farm waste management.

2.4. Comparative Study

Urine samples were obtained in parallel with muscle and blood samples gathered for the study performed by Serrano et al. [54]. That study’s aim was to find a suitable matrix for ante mortem tests for the detection of antimicrobial compounds, which would avoid the slaughter of contaminated animals and thus the entrance of antimicrobial compounds into the food chain. The matrix should be characterized via an easy extraction procedure from living animals and a good correlation with the concentration found in muscle. Whilst blood proved to fulfil both requirements [54], urine results obtained in the present study showed that urine is not a suitable matrix for that purpose (Figure 4). These findings agree with those described previously by Seymour et al. [55] for cows: urine samples from treated cows tested positive for the presence of antimicrobial residues even after the end of the withdrawal period set by the manufacturer. Moreover, this issue could also be interpreted as the occurrence of higher levels of antimicrobials in urine compared to other tissues such as muscle.
Figure 4 describes the correlation between the concentration of sulfamethoxypyrydazine (Figure 4a), oxytetracycline (Figure 4b), and enrofloxacin (Figure 4c) in muscle and urine. With the exception of sulfamethoxypyrydazine, concentrations described in urine were much higher than the ones described for muscle. This indicates that antibiotics might be eliminated for periods of time longer than those required by the European maximum residue limits for muscle [56]. Higher concentrations in urine compared to muscle are common and have been previously described for several antimicrobials such as oxytetracycline, florfenicol, tylosin, sulfadiazine, trimetropim, and enrofloxacin in food-producing swine [13].
Although the high concentrations described in urine open up new possibilities for urine applications in the field of detection tests for antimicrobial residues (for instance, to detect illegal treatments or to ensure that a production system remains free of antibiotics), they also point to the imperative need of controlling farm residues, as most of the antimicrobials removed by urine remain unaltered or are transformed into metabolites of the administered compound [49,50]. Antimicrobials used in this study are between the most commonly used in Europe and are included in novel studies about soil vulnerability to antibiotic contamination [57]. Fertilization of fields with manure and slurry could spread these residues to the fields close to farms when fertilizing them. This practice is increasingly considered a concern [58], mainly due to the impact on natural microbial communities [58,59,60] and the potential spread of antibiotic resistant bacteria and antibiotic resistance genes [58,61]. Moreover, antimicrobial residues reach surface waters and groundwater by means of leaching [62], reaching distant areas and even water used by industry or for human supply. In an attempt to tackle this problem, the EMA has developed a guideline on environmental impact assessment of new veterinary pharmaceuticals [63]. This guide proposes that the estimation of the total release of antimicrobials is used as the key to assess their safety, following a similar philosophy as the one performed in the current study. Nonetheless, good management of slurry is essential in order to deal with the problem of uncontrolled antimicrobial delivery, but as not all the antimicrobials present the same elimination rates, a good knowledge on the subject of their excretion is thus required to improve waste treatment.
Referring back to antimicrobial excretion, the concentration in urine followed an exponential rate of elimination regardless of the antimicrobial tested (Figure 5). Nevertheless, among compounds, depletion rates differed (p < 0.05), and thus the concentrations measured each day differed as well. The highest concentrations at the beginning of the withdrawal period were described for oxytetracycline (data obtained from the regression). This circumstance, along with the slowest rate of removal described in this study (half-life of 4.18 days, Table 1), indicates that this compound might be a problematic antibacterial residue in terms of farm waste management.
Enrofloxacin had a half-life of 1.48 days and sulfamethoxypyridazine of 0.49 days (Table 1). Thus, considering the extended half-life of oxytetracycline, urine removal rates described by these antimicrobials differed by up to nearly 10 times. Good knowledge regarding their excretion is thus critical in order to avoid uncontrolled delivery of antibacterial compounds to a farm’s surroundings.
As defined by the European Medicine Agency [6], sulfonamides and tetracyclynes belong to category D in the classification of antibiotic classes for veterinary use, which means that they should be the first treatment choice. Meanwhile, enrofloxacin pertains to category B; it is of major relevance in human medicine and should be used only when no equivalently effective antimicrobials in categories C or D can be found. These considerations are nevertheless restricted to the EMA’s actual recommendations regarding a responsible use of antimicrobials, designed to encourage veterinarians to carry out an antibiogram before prescribing an antimicrobial treatment.
Thus, in the case of equal sensitivity to the antimicrobials studied, sulfamethoxypyrydazine and oxytetracycline would be the treatments to suggest. In terms of waste management and in view of the data presented in this study, sulfamethoxypyridazine would be the ideal one of the two, as it is more rapidly eliminated in urine. This fast excretion rate implies short periods of extra waste treatment, leading to energetic reduction and economic savings while minimizing the delivery of antibacterial residues to the environment. However, the increase in antimicrobial resistances investigated in recent years [64] and the widespread description of sulfonamide resistance in different niches such as wastewaters, sewage, aquaculture, compost, and even the meat food supply chain [65,66,67] might make these compounds useless against an outbreak etiological agent [68,69], thus making it necessary to give preference to another antibiotic instead. In case such a situation arises, and for purposes of responsible waste management, the sequence of selection would be proportional to the rate of removal: antimicrobials with faster rates of removal would be the therapeutics of choice.

3. Materials and Methods

3.1. Urine Samples

3.1.1. Antimicrobials

The antimicrobials selected for animal treatment were sulfamethoxypyridazine (a sulfonamide), oxytetracycline (a tetracycline), and enrofloxacin (a quinolone) as they are among the most widely used antimicrobials in EU farming production; they follow different metabolic pathways [70], and they are all effective against a wide range of bacteria. Each of these compounds was administered via intramuscular (IM) injection. Table 2 shows the main features of the antimicrobial compounds used.

3.1.2. Collection of Urine Samples Containing In Vivo Injected Antibiotics

A total of 66 previously untreated piglets were procured at treatment onset. Starting at 40 days before administration of the compounds, they were kept on the premises of the Faculty of Veterinary Sciences at the University of Zaragoza (Zaragoza, Spain) and used in tandem for another study [54]. Pigs were provided by a commercial farm (Valporgen S.L., Zaragoza, Spain), their genetics were Landrace × Large White, and they weighed an average of 44.9 ± 4.8 kg at reception. From them, 39 were female and 27, male. During acclimatization and withdrawal periods, the piglets were fed ad libitum with a special mixed feed free of antibiotics (ARS Alendi S.A., Huesca, Spain), and water was provided from a separate, controlled water circuit. Piglets were raised in separate pens depending on the antibiotic with which they were administrated. Table 2 summarizes the main characteristics of the treatments carried out with each antimicrobial.
Overall, 4 pigs remained untreated as blank sample references, and 62 pigs were treated: 20 were administered with sulfamethoxypyridazine, 20 with oxytetracycline, and 22 with enrofloxacin. Urine was collected on different days within the withdrawal period determined by the respective antimicrobial drug manufacturers. It was collected from live pigs via mobilization of the animal and bladder stimulation. At pre-set time intervals, pigs were slaughtered and urine was obtained via bladder puncture; at the same time, urine was gathered from living animals subjected to the same treatment and withdrawal period. Consequently, urine was collected from 1 to 9 pigs on each day of analysis. As animals were bred in batches and slaughtered all along the withdrawal period, the number of sampled animals decreased as the withdrawal period progressed. Samples were kept aliquoted and frozen at −20 °C until analysis.

3.1.3. Ethical Approval

The study was carried out in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) initiative and approved by the Animal Ethics Experimentation Committee of the University of Zaragoza (PI58/17). Animals were handled and used in accordance with the Spanish Animal Protection Policy RD 53/2013 [71], which complies with the European Union Directive 2010/63 [72] on the protection of animals used for experimental and other scientific purposes.

3.2. LC-MS/MS Analysis

3.2.1. Standards and Reagents

LC-MS/MS grade solvents were from Fisher Chemical (Fisher Scientific, Leics, UK). Formic acid (98–100%) was from Fisher Chemical (Fisher Scientific, Geel, Belgium). Purified water was obtained through a Milli-Q system (Millipore, Merck KGaA, Darmstadt, Germany). Ciprofloxacin, enrofloxacin, oxytetracycline, and sulfamethoxypyridazine, as well as internal standard (IS) demeclocycline, were made by Vetranal (Sigma-Aldrich AG, Buchs, Switzerland). Enrofloxacin-d8 and sulfamethoxypyridazine-d3 were purchased from Witega (Witega, Berlin, Germany). For the preparation of 0.1 M EDTA, 3.72 g of EDTA Na2·H2O (>98%, Sigma-Aldrich Chemie, Steinheim, Germany) were dissolved and mixed with up to 100 mL of distilled water.
Stock solutions (1 mg mL−1) for each standard were prepared in methanol and kept at −20 °C. Spiking solution contained each of the studied analytes at 0.6 µg mL−1, and IS spiking solution contained 1.2 µg mL−1 of each IS. Both solutions were prepared in methanol and maintained at −20 °C.

3.2.2. Sample Preparation

1.5 mL of urine were spiked with 100 µL of IS spiking solution. 100 µL 0.1M EDTA and 5 mL of purified water were added and mixed. 500 µL were taken and further diluted with 1500 µL of purified water. It was filtered through 0.2 µm directly into HPLC vials.

3.2.3. LC-MS/MS Determination

All urine samples were analysed using a SCIEX Exion LC coupled to a TripleQuad 6500+ triple quadrupole detector equipped with an Acquity UPLC® BEH C18 column (1.7 µm, 2.1 × 100 mm). The mobile phase consisted of eluent A (0.1% formic acid in water) and eluent B (0.1% formic acid in acetonitrile) at a flow rate of 0.4 mL min−1. The gradient started at 5%B, increased at a constant rate until 40%B in 3.75 min, then increased in a second ramp until 95%B in 4.37 min, held constant until 5.00 min, then returned to the initial 5% and held constant until 7.00 min. The injected volume was 5 µL. Positive electrospray ionisation was used, and analytes were detected in MRM mode by monitoring 2 transitions for each compound of interest (Table 3). Regardless of the compound analysed, the technique’s limit of detection (LoD) was 10 ppb.

3.3. Pharmacokinetic Parameters and Statistical Analysis

For each day of the withdrawal period pre-set in this study to evaluate the behaviour of antimicrobials, 1 to 9 samples of urine coming from different animals subjected to the same treatment and withdrawal period were analysed via LC-MS/MS. Results were represented as the mean ± standard deviation using the PRISM® program (GraphPad Software, Inc., San Diego, CA, USA).
The rates of elimination (λz) of antibiotics from urine were determined via regression analysis. The corresponding half-lives of elimination(T1/2) were calculated according to the following equation:
Equation (1): Half-life of elimination where T 1 / 2 is the half-life of elimination and λ Z is the rate of elimination.
T 1 / 2 = L n   ( 2 ) λ z
Data obtained were analysed and submitted to comparison of averages via ANOVA, followed by a post hoc Tukey test and t-tests with GraphPad PRISM®. Differences were considered significant if p < 0.05.

4. Conclusions

Most of the antibiotics commonly used in chemotherapy are removed from animals´ bodies via urine, thereby contaminating farm wastes, which, if not properly treated, might reach the surroundings, contributing to the dissemination of AMR. To avoid this, a good choice of antimicrobial compound for therapy is required, along with accurate waste management. The study of three widely used antimicrobials showed high excretion rates via urine. This finding has great potential in terms of antibiotic control on the farm level, although it necessarily requires that producers perform slurry purification. Sulfamethoxypyridazine proved to be rapidly excreted by urine (a half-life time of 0.49 days) and enrofloxacin had an intermediate rate of removal by urine (1.48 days); conversely, oxytetracycline took much longer (4.18 days). Hence, after the study of these compounds’ removal rates, at equal susceptibility of the target microorganism, sulfamethoxypyridazine would be the treatment of choice, proving that an in-depth study of the excretion pathways of antimicrobials used in farms will help farmers and producers to choose the most appropriate one in order to optimize waste management and avoid the emergence of AMR while preserving the global One Health approach.

Author Contributions

Conceptualization and methodology, M.J.S., D.G.-G., E.A., O.M., M.V.F., A.L., C.B., L.M., S.C. and R.P.; formal analysis, M.J.S., E.A., L.M., S.C. and R.P.; Investigation, M.J.S., D.G.-G., E.A., J.E., O.M., M.V.F., A.L., C.B. and R.P.; resources, M.J.S., O.M., M.V.F., A.L., C.B., L.M., S.C. and R.P.; data curation, M.J.S., E.A. and R.P.; writing—original draft preparation, M.J.S. and R.P.; writing—review and editing, M.J.S., D.G.-G., E.A., O.M., M.V.F., A.L., C.B., L.M., S.C. and R.P.; project administration, M.J.S. and R.P.; funding acquisition, S.C. and R.P. All authors have read and agreed to the published version of the manuscript.

Funding

This project was 65% co-financed by the European Regional Development Fund (ERDF) through the Interreg V-A Spain-France-Andorra programme (POCTEFA (Programa INTERREG V-A España-Francia-Andorra) 2014–2020) (EFA (España-Francia-Andorra) 152/16). POCTEFA aims to reinforce the economic and social integration of the French–Spanish Andorran border. Its support is focused on developing economic, social, and environmental cross-border activities through joint strategies favouring sustainable territorial development.

Institutional Review Board Statement

The study was carried out in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) initiative and approved by the Animal Ethics Experimentation Committee of the University of Zaragoza (PI58/17). Animals were handled and used in accordance with the Spanish Animal Protection Policy RD 53/2013, which complies with the European Union Directive 2010/63 on the protection of animals used for experimental and other scientific purposes.

Data Availability Statement

Data is contained within the article.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Brown, K.; Uwiera, R.R.; Kalmokoff, M.L.; Brooks, S.P.; Inglis, G.D. Antimicrobial growth promoter use in livestock: A requirement to understand their modes of action to develop effective alternatives. Int. J. Antimicrob. Agents 2007, 49, 12–24. [Google Scholar] [CrossRef]
  2. Diana, A.; Santinello, M.; Penasa, M.; Scali, F.; Magni, E.; Alborali, G.L.; Bertocchi, L.; De Marchi, M. Use of antimicrobials in beef cattle: An observational study in the north of Italy. Prev. Vet. Med. 2020, 81, 105032. [Google Scholar] [CrossRef] [PubMed]
  3. Van Boeckel, T.P.; Glennon, E.E.; Chen, D.; Gilbert, M.; Robinson, T.P.; Grenfell, B.T.; Levin, S.A.; Bonhoeffer, S.; Laxminarayan, R. Reducing antimicrobial use in food animals. Science 2017, 357, 1350–1352. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. O’Neill, J. Antimicrobials in agriculture and the environment: Reducing unnecessary use and waste. In The Review on Antimicrobial Resistance; Wellcome Trust, HM Government: London, UK, 2015; pp. 1–44. Available online: https://amr-review.org/sites/default/files/Antimicrobials%20in%20agriculture%20and%20the%20environment%20-%20Reducing%20unnecessary%20use%20and%20waste.pdf (accessed on 19 November 2020).
  5. Tang, K.L.; Caffrey, N.P.; Nobrega, D.B.; Cork, S.C.; Ronksley, P.E.; Barkema, H.W.; Polachek, A.J.; Ganshron, H.; Sharma, N.; Kellner, J.D.; et al. Restricting the use of antibiotics in food-producing animals and its associations with antibiotic resistance in food-producing animals and human beings: A systematic review and meta-analysis. Lancet Planet Health 2017, 1, 316–327. [Google Scholar] [CrossRef]
  6. EMA (European Medicine Agency). Categorisation of Antibiotics for Use in Animals for Prudent and Responsible Use. 2020. Available online: https://www.ema.europa.eu/en/documents/report/infographic-categorisation-antibiotics-use-animals-prudent-responsible-use_en.pdf (accessed on 27 April 2021).
  7. Regulation (EU) 2019/4 of the European Parliament and of the Council of 11 December 2018 on the manufacture, placing on the market and use of medicated feed, amending Regulation (EC) No. 183/2005 of the European Parliament and of the Council and repealing Council Directive 90/167/EEC. Off. J. Eur. Union 2019, L. 4, 1–23. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32019R0004 (accessed on 23 March 2021).
  8. Regulation (EU) 2019/6 of the European Parliament and of the Council of 11 December 2018 on veterinary medicinal products and repealing Directive 2001/82/EC. Off. J. Eur. Union 2019, L. 4, 43–167. Available online: https://www.legislation.gov.uk/eur/2019/6 (accessed on 23 March 2021).
  9. Riviere, J.E.; Spoo, J.W. Chapter 42. Tetracycline antibiotics. In Veterinary Pharmacology and Therapeutics, 8th ed.; Adams, R.H., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 828–940. [Google Scholar]
  10. Papich, M.G.; Riviere, J.E. Chapter 45. Fluoroquinolone antimicrobial drugs. In Veterinary Pharmacology and Therapeutics, 8th ed.; Adams, R.H., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 898–917. [Google Scholar]
  11. Vaden, S.L.; Riviere, J.E. Chapter 41. Penicillins and related β-lactam antibiotics. In Veterinary Pharmacology and Therapeutics, 8th ed.; Adams, R.H., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 818–827. [Google Scholar]
  12. Qiu, J.; Zhao, T.; Liu, Q.; He, J.; He, D.; Wu, G.; Li, Y.; Jiang, C.; Xu, Z. Residual veterinary antibiotics in pig excreta after oral administration of sulfonamides. Environ. Geochem. Health 2016, 38, 549–556. [Google Scholar] [CrossRef]
  13. Chiesa, L.M.; Nobile, M.; Panseri, S.; Arioli, F. Antibiotic use in heavy pigs: Comparison between urine and muscle samples from food chain animals analysed by HPLC-MS/MS. Food Chem. 2017, 235, 111–118. [Google Scholar] [CrossRef] [PubMed]
  14. Ahmed, M.B.; Zhou, J.L.; Ngo, H.H.; Guo, W.S. Adsorptive removal of antibiotics from water and wastewater: Progress and challenges. Sci. Total Environ. 2015, 532, 112–116. [Google Scholar] [CrossRef] [PubMed]
  15. Ahmed, M.B.; Zhou, J.L.; Ngo, H.H.; Guo, W.S.; Johir, M.A.H.; Sornalingam, K. Single and competitive sorption properties and mechanism of functionalized biochar for removing sulfonamide antibiotics from water. Chem. Eng. J. 2017, 311, 348–358. [Google Scholar] [CrossRef]
  16. Zhao, H.; Liu, X.; Cao, Z.; Zhan, Y.; Shi, X.; Yang, Y.; Zhou, J.; Xu, J. Adsorption behavior and mechanism of chloramphenicols, sulfonamides, and nonantibiotic pharmaceuticals on multi-walled carbon nanotubes. J. Hazard. Mater. 2016, 310, 235–245. [Google Scholar] [CrossRef] [PubMed]
  17. Wang, B.; Jiang, Y.S.; Li, F.Y.; Yang, D.Y. Preparation of biochar by simultaneous carbonization, magnetization and activation for norfloxacin removal in water. Bioresour. Technol. 2017, 233, 159–165. [Google Scholar] [CrossRef] [PubMed]
  18. Ahmed, M.B.; Zhou, J.L.; Ngo, H.H.; Guo, W.S.; Thomaidis, N.S.; Xu, J. Progress in the biological and chemical treatment technologies for emerging contaminant removal from wastewater: A critical review. J. Hazard. Mater. 2017, 323, 274–298. [Google Scholar] [CrossRef] [PubMed]
  19. Seifrtová, M.; Nováková, L.; Lino, C.; Pena, A.; Solich, P. An overview of analytical methodologies for the determination of antibiotics in environmental waters. Anal. Chim. Acta 2009, 649, 158–179. [Google Scholar] [CrossRef] [PubMed]
  20. Haller, M.Y.; Müller, S.R.; McArdell, C.S.; Alder, A.C.; Suter, M.J.F. Quantification of veterinary antibiotics (sulfonamides and trimethoprim) in animal manure by liquid chromatography–mass spectrometry. J. Chromatogr. A 2002, 952, 111–120. [Google Scholar] [CrossRef]
  21. Schlüsener, M.P.; Bester, K.; Spiteller, M. Determination of antibiotics such as macrolides, ionophores and tiamulin in liquid manure by HPLC–MS/MS. Anal. Bioanal. Chem. 2003, 375, 942–947. [Google Scholar] [CrossRef]
  22. Zhou, X.; Wang, J.; Lu, C.; Liao, Q.; Gudda, F.O.; Ling, W. Antibiotics in animal manure and manure-based fertilizers: Occurrence and ecological risk assessment. Chemosphere 2020, 255, 127006. [Google Scholar] [CrossRef]
  23. Halling-Sørensen, B.; Nors Nielsen, S.; Lanzky, P.F.; Ingerslev, F.; Holten Lutzhoft, H.C.; Jorgensen, S.E. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere 1998, 36, 357–393. [Google Scholar] [CrossRef]
  24. Wang, Q.; Guo, M.; Yates, S.R. Degradation kinetics of manure derived sulfadimethoxine in amended soil. J. Agric. Food Chem. 2006, 54, 157–163. [Google Scholar] [CrossRef]
  25. Tolls, J. Sorption of veterinary pharmaceuticals in soils: A review. Crit. Rev. Environ. Sci. Technol. 2001, 35, 3397–3406. [Google Scholar] [CrossRef]
  26. Hamscher, G.; Pawelzick, H.T.; Höper, H.; Nau, H. Different behavior of tetracyclines and sulfonamides in sandy soils after repeated fertilization with liquid manure. Environ. Toxicol. Chem. 2005, 24, 861–868. [Google Scholar] [CrossRef] [PubMed]
  27. Sarmah, A.K.; Meyer, M.T.; Boxall, A.B.A. A global perspective on the use, sales, exposure pathways, occurrence, fate and effects of veterinary antibiotics (VAs) in the environment. Chemosphere 2006, 65, 725–729. [Google Scholar] [CrossRef] [PubMed]
  28. Kolpin, D.W.; Furlong, E.T.; Meyer, M.T.; Thurman, E.M.; Zaugg, S.D.; Barber, L.B.; Buxton, H.T. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999–2000: A national reconnaissance. Environ. Sci. Technol. 2002, 36, 1202–1211. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  29. Baran, W.; Adamek, E.; Ziemianska, J.; Sobczak, A. Effects of the presence of sulfonamides in the environment and their influence on human health. J. Hazard. Mater. 2011, 196, 1–15. [Google Scholar] [CrossRef] [PubMed]
  30. Tian, L.; Khalil, S.; Bayen, S. Effect of thermal treatments on the degradation of antibiotic residues in food. Crit. Rev. Food Sci. Nutr. 2017, 57, 3760–3770. [Google Scholar] [CrossRef] [PubMed]
  31. Chu, L.; Chen, D.; Wang, J.; Yang, Z.; Yang, Q.; Shen, Y. Degradation of antibiotics and inactivation of antibiotic resistance genes (ARGs) in Cephalosporin C fermentation residues using ionizing radiation, ozonation and thermal treatment. J. Hazard. Mater. 2020, 382, 121058. [Google Scholar] [CrossRef] [PubMed]
  32. Gros, M.; Marti, E.; Balcázar, J.L.; Boy-Roura, M.; Busquets, A.; Colon, J.; Sanchez-Melsio, A.; Lekunberri, I.; Borrego, C.M.; Ponsá, S.; et al. Fate of pharmaceuticals and antibiotic resistance genes in a full-scale on-farm livestock waste treatment plant. J. Hazard. Mater. 2019, 378, 120716. [Google Scholar] [CrossRef] [PubMed]
  33. Han, Y.; Yang, L.; Chen, X.; Cai, Y.; Zhang, X.; Qian, M.; Chen, X.; Zhao, H.; Sheng, M.; Cao, G.; et al. Removal of veterinary antibiotics from swine wastewater using anaerobic and aerobic biodegradation. Sci. Total Environ. 2020, 709, 136094. [Google Scholar] [CrossRef]
  34. Gurmessa, B.; Pedretti, E.F.; Cocco, S.; Cardelli, V.; Corti, G. Manure anaerobic digestion effects and the role of pre-and post-treatments on veterinary antibiotics and antibiotic resistance genes removal efficiency. Sci. Total Environ. 2020, 721, 137532. [Google Scholar] [CrossRef]
  35. Zhang, M.; He, L.Y.; Liu, Y.S.; Zhao, J.L.; Liu, W.R.; Zhang, J.N.; Chen, J.; He, L.K.; Zhang, Q.Q.; Ying, G.G. Fate of veterinary antibiotics during animal manure composting. Sci. Total Environ. 2019, 650, 1363–1370. [Google Scholar] [CrossRef] [PubMed]
  36. Marti, E.; Gros, M.; Boy-Roura, M.; Ovejero, J.; Busquets, A.M.; Colón, J.; Petrovic, M.; Ponsá, S. Pharmaceuticals removal in an on-farm pig slurry treatment plant based on solid-liquid separation and nitrification-denitrification systems. J. Waste Manag. 2020, 102, 412–419. [Google Scholar] [CrossRef] [PubMed]
  37. Pérez-Moya, M.; Graells, M.; Castells, G.; Amigó, J.; Ortega, E.; Buhigas, G.; Pérez, L.M.; Mansilla, H.D. Characterization of the degradation performance of the sulfamethazine antibiotic by photo-Fenton process. Water Res. 2010, 44, 2533–2540. [Google Scholar] [CrossRef] [PubMed]
  38. Pruden, A.; Larsson, D.J.; Amézquita, A.; Collignon, P.; Brandt, K.K.; Graham, D.W.; Lazorchak, J.M.; Suzuki, S.; Silley, P.; Snape, J.R.; et al. Management options for reducing the release of antibiotics and antibiotic resistance genes to the environment. Environ. Health Perspect. 2013, 121, 878–885. [Google Scholar] [CrossRef] [PubMed]
  39. Thomas, G.K.; Millar, R.G.; Anstis, P.W. Stability of sulfonamide antibiotics in spiked pig liver tissue during frozen storage. J. AOAC Int. 1997, 80, 988–996. [Google Scholar] [CrossRef] [Green Version]
  40. Berendsen, B.J.A.; Elbers, I.J.W.; Stolker, A.A.M. Determination of the stability of antibiotics in matrix and reference solutions using a straightforward procedure applying mass spectrometric detection. Food Addit. Contam. Part A 2011, 28, 1657–1666. [Google Scholar] [CrossRef] [PubMed]
  41. Spoo, J.W.; Riviere, J.E. Chapter 40. Sulfonamides. In Veterinary Pharmacology and Therapeutics, 8th ed.; Adams, R.H., Ed.; Iowa State University Press: Ames, IA, USA, 2001; pp. 796–817. [Google Scholar]
  42. Benchaoui, H.A.; Nowakowski, M.; Sherington, J.; Rowan, T.G.; Sunderland, S.J. Pharmacokinetics and lung tissue concentrations of tulathromycin in swine. J. Vet. Pharmacol. Ther. 2004, 27, 203–210. [Google Scholar] [CrossRef] [PubMed]
  43. Mengelers, M.J.B.; van Gogh, E.R.; Huveneers, M.B.M.; Hougee, P.E.; Kuiper, H.A.; Pijpers, A.; Verheijden, J.H.; Van Miert, A.S. Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single-and multiple-dose administration to healthy pigs. Vet. Res. Commun. 2001, 25, 461–481. [Google Scholar] [CrossRef]
  44. Mengelers, M.J.B.; Van Gogh, E.R.; Kuiper, H.A.; Pijpers, A.; Verheijden, J.H.; Van Miert, A.S. Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs. J. Vet. Pharmacol. Ther. 1995, 18, 243–253. [Google Scholar] [CrossRef]
  45. Zhang, M.; Liu, Y.S.; Zhao, J.L.; Liu, W.R.; He, L.Y.; Zhang, J.N.; Chen, J.; He, L.K.; Zhang, Q.Q.; Ying, G.G. Occurrence, fate and mass loadings of antibiotics in two swine wastewater treatment systems. Sci. Total Environ. 2018, 639, 1421–1431. [Google Scholar] [CrossRef]
  46. Ziółkowski, H.; Grabowski, T.; Jasiecka, A.; Zuśka-Prot, M.; Barski, D.; Jaroszewski, J.J. Pharmacokinetics of oxytetracycline in broiler chickens following different routes of administration. Vet. J. 2016, 208, 96–98. [Google Scholar] [CrossRef]
  47. El Korchi, G.; Prats, C.; Arboix, M.; Pérez, B. Disposition of oxytetracycline in pigs after administration of two long-acting formulations. J. Vet. Pharmacol. Ther. 2001, 24, 247–250. [Google Scholar] [CrossRef] [PubMed]
  48. Zhi, S.; Shen, S.; Zhou, J.; Ding, G.; Zhang, K. Systematic analysis of occurrence, density and ecological risks of 45 veterinary antibiotics: Focused on family livestock farms in Erhai Lake basin, Yunnan, China. Environ. Pollut. 2020, 267, 115539. [Google Scholar] [CrossRef]
  49. Chee-Sanford, J.C.; Aminov, R.I.; Krapac, I.J.; Garrigues-Jeanjean, N.; Mackie, R.I. Occurrence and diversity of tetracycline resistance genes in lagoons and groundwater underlying two swine production facilities. Appl. Environ. Microbiol. 2001, 67, 1494–1502. [Google Scholar] [CrossRef] [Green Version]
  50. Mackie, R.I.; Koike, S.; Krapac, I.; Chee-Sanford, J.; Maxwell, S.; Aminov, R.I. Tetracycline residues and tetracycline resistance genes in groundwater impacted by swine production facilities. Anim. Biotechnol. 2006, 17, 157–176. [Google Scholar] [CrossRef]
  51. Koike, S.; Krapac, I.G.; Oliver, H.D.; Yannarell, A.C.; Chee-Sanford, J.C.; Aminov, R.I.; Mackie, R.I. Monitoring and source tracking of tetracycline resistance genes in lagoons and groundwater adjacent to swine production facilities over a 3-year period. Appl. Environ. Microbiol. 2007, 73, 4813–4823. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  52. Nielsen, P.; Gyrd-Hansen, N. Bioavailability of enrofloxacin after oral administration to fed and fasted pigs. Pharmacol. Toxicol. 1997, 80, 246–250. [Google Scholar] [CrossRef] [PubMed]
  53. Messenger, K.M.; Papich, M.G.; Blikslager, A.T. Distribution of enrofloxacin and its active metabolite, using an in vivo ultrafiltration sampling technique after the injection of enrofloxacin to pigs. J. Vet. Pharmacol. Ther. 2012, 35, 452–459. [Google Scholar] [CrossRef] [PubMed]
  54. Serrano, M.J.; Mitjana, O.; Bonastre, C.; Laborda, A.; Falceto, M.V.; García-Gonzalo, D.; Abilleira, E.; Elorduy, J.; Bousquet-Melou, A.; Mata, L.; et al. Is blood a good indicator for detecting antimicrobials in meat? Evidence for the development of in vivo surveillance methods. Antibiotics 2020, 9, 175. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Seymour, E.H.; Jones, G.M.; McGilliard, M.L. Comparisons of on-farm screening tests for detection of antibiotic residues. J. Dairy Sci. 1988, 71, 539–544. [Google Scholar] [CrossRef]
  56. Commission Regulation (EU) No. 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin. Off. J. Eur. Union 2010, L. 15, 1–72. Available online: https://ec.europa.eu/health/sites/default/files/files/eudralex/vol-5/reg_2010_37/reg_2010_37_en.pdf (accessed on 23 March 2021).
  57. De la Torre, A.; Iglesias, I.; Carballo, M.; Ramírez, P.; Muñoz, M.J. An approach for mapping the vulnerability of European Union soils to antibiotic contamination. Sci. Total Environ. 2012, 414, 672–679. [Google Scholar] [CrossRef] [PubMed]
  58. Kemper, N. Veterinary antibiotics in the aquatic and terrestrial environment. Ecol. Indic. 2008, 8, 1–13. [Google Scholar] [CrossRef]
  59. Martinez, J.L. Environmental pollution by antibiotics and by antibiotic resistance determinants. Environ. Pollut. 2009, 157, 2893–2902. [Google Scholar] [CrossRef] [PubMed]
  60. Jechalke, S.; Focks, A.; Rosendahl, I.; Groeneweg, J.; Siemens, J.; Heuer, H.; Smalla, K. Structural and functional response of the soil bacterial community to application of manure from difloxacin-treated pigs. FEMS Microbiol. Ecol. 2014, 87, 78–88. [Google Scholar] [CrossRef] [PubMed]
  61. Heuer, H.; Schmitt, H.; Smalla, K. Antibiotic resistance gene spread due to manure application on agricultural fields. Curr. Opin. Microbiol. 2011, 14, 236–243. [Google Scholar] [CrossRef]
  62. Kim, K.-R.; Owens, G.; Kwon, S.-I.; So, K.-H.; Lee, D.-B.; Ok, Y.S. Occurrence and environmental fate of veterinary antibiotics in the terrestrial environment. Water Air Soil Pollut. 2011, 214, 163–174. [Google Scholar] [CrossRef]
  63. European Medicines Agency. Guideline on Environmental Impact Assessment for Veterinary Medicinal Products in Support of the VICH Guidelines GL6 and GL38, EMA/CVMP/ERA/418282/2005-Rev.1-Corr; European Medicines Agency: London, UK, 2016. [Google Scholar]
  64. Livermore, D.M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64, i29–i36. [Google Scholar] [CrossRef] [Green Version]
  65. Trobos, M.; Jakobsen, L.; Olsen, K.E.; Frimodt-Møller, N.; Hammerum, A.M.; Pedersen, K.; Agerso, Y.; Porsbo, L.J.; Olsen, J.E. Prevalence of sulphonamide resistance and class 1 integron genes in Escherichia coli isolates obtained from broilers, broiler meat, healthy humans and urinary infections in Denmark. Int. J. Antimicrob. Agents 2008, 32, 367–369. [Google Scholar] [CrossRef]
  66. Adekanmbi, A.O.; Adejoba, A.T.; Banjo, O.A.; Saki, M. Detection of sul1 and sul2 genes in sulfonamide-resistant bacteria (SRB) from sewage, aquaculture sources, animal wastes and hospital wastewater in south-west Nigeria. Gene Rep. 2020, 20, 100742. [Google Scholar] [CrossRef]
  67. Lin, H.; Sun, W.; Jin, D.; Yu, Q.; Yang, Y.; Zhang, Z.; Sun, P.; Ma, J. Effect of composting on the conjugative transmission of sulfonamide resistance and sulfonamide-resistant bacterial population. J. Clean. Prod. 2021, 285, 125483. [Google Scholar] [CrossRef]
  68. Tempini, P.N.; Aly, S.S.; Karle, B.M.; Pereira, R.V. Multidrug residues and antimicrobial resistance patterns in waste milk from dairy farms in Central California. J. Dairy Sci. 2018, 101, 8110–8122. [Google Scholar] [CrossRef] [PubMed]
  69. Sodhi, K.K.; Kumar, M.; Singh, D.K. Insight into the amoxicillin resistance, ecotoxicity, and remediation strategies. J. Water Process Eng. 2021, 39, 101858. [Google Scholar] [CrossRef]
  70. Riviere, J.E. Absorption, distribution, metabolism, and elimination. In Veterinary Pharmacology and Therapeutics, 9th ed.; Riviere, J.E., Papich, M.G., Eds.; Willey Blackwell: Ames, IA, USA, 2009; pp. 11–46. [Google Scholar]
  71. Real Decreto 53/2013, de 1 de febrero, por el que se establecen las normas básicas aplicables para la protección de los animales utilizados en experimentación y otros fines científicos, incluyendo la docencia. Boletín Oficial Estado 2013, 34, 11370–11421.
  72. Directive 2010/63/EU of the European Parliament and of the Council of 22 September 2010 on the protection of animals used for scientific purposes. Off. J. Eur. Union 2010, L. 276, 33–79. Available online: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32010L0063 (accessed on 23 March 2021).
Antibiotics 10 00762 g001 550
Figure 1. Occurrence of the concentration of sulfamethoxypyridazine in urine samples obtained from pigs treated with sulfamethoxypyridazine at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined via liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for sulfamethoxypyridazine.
Figure 1. Occurrence of the concentration of sulfamethoxypyridazine in urine samples obtained from pigs treated with sulfamethoxypyridazine at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined via liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for sulfamethoxypyridazine.
Antibiotics 10 00762 g001
Antibiotics 10 00762 g002 550
Figure 2. Occurrence of the concentration of oxytetracycline in urine samples obtained from pigs treated with oxytetracycline at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined by liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for oxytetracycline.
Figure 2. Occurrence of the concentration of oxytetracycline in urine samples obtained from pigs treated with oxytetracycline at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined by liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for oxytetracycline.
Antibiotics 10 00762 g002
Antibiotics 10 00762 g003 550
Figure 3. Occurrence of the concentration of enrofloxacin in urine samples obtained from pigs treated with enrofloxacin at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined via liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for enrofloxacin.
Figure 3. Occurrence of the concentration of enrofloxacin in urine samples obtained from pigs treated with enrofloxacin at pre-set intervals within the withdrawal period (when day 0 matches the end of the treatment), determined via liquid chromatography with tandem mass spectrometry (LC-MS/MS). The LoD dotted line represents the detection limit of the analytical technique for enrofloxacin.
Antibiotics 10 00762 g003
Antibiotics 10 00762 g004 550
Figure 4. Relationship among the concentrations of sulfamethoxypyridazine (a), oxytetracycline (b), and enrofloxacin (c) detected in muscle and urine samples. The bisecting dotted line represents the 1:1 correlation if both matrixes contained the same concentration of enrofloxacin.
Figure 4. Relationship among the concentrations of sulfamethoxypyridazine (a), oxytetracycline (b), and enrofloxacin (c) detected in muscle and urine samples. The bisecting dotted line represents the 1:1 correlation if both matrixes contained the same concentration of enrofloxacin.
Antibiotics 10 00762 g004
Antibiotics 10 00762 g005 550
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyridazine ( Antibiotics 10 00762 i001), oxytetracycline ( Antibiotics 10 00762 i002), and enrofloxacin ( Antibiotics 10 00762 i003) in urine after animal treatment within the withdrawal period. The LoD dotted line represents the detection limit of the analytical technique for sulfamethoxypyridazine, oxytetracycline, and enrofloxacin.
Figure 5. Comparison between the concentrations and rates of removal found for sulfamethoxypyridazine ( Antibiotics 10 00762 i001), oxytetracycline ( Antibiotics 10 00762 i002), and enrofloxacin ( Antibiotics 10 00762 i003) in urine after animal treatment within the withdrawal period. The LoD dotted line represents the detection limit of the analytical technique for sulfamethoxypyridazine, oxytetracycline, and enrofloxacin.
Antibiotics 10 00762 g005
Table
Table 1. Half-lives of elimination (T1/2) calculated using Equation (1) and estimated times for the complete removal from urine determined for sulfamethoxypyridazine, oxytetracycline, and enrofloxacin expressed in days.
Table 1. Half-lives of elimination (T1/2) calculated using Equation (1) and estimated times for the complete removal from urine determined for sulfamethoxypyridazine, oxytetracycline, and enrofloxacin expressed in days.
Antibacterial MoleculeSlope1R22λzT1/2Estimated Time for Complete Excretion
Sulfamethoxypyridazine0.6144 ± 0.10520.990.710.496.89
Oxytetracycline0.07194 ± 0.0150.646.044.1863.38
Enrofloxacin0.2027 ± 0.07600.472.141.4820.48
1R2 coefficient describes the goodness of the fit found for the occurrence of the antimicrobial´s removal by urine. 2 λZ: rate of elimination.
Table
Table 2. Source and main characteristics of the antimicrobials explored. Both administration patterns and withdrawal periods are recommended by the manufacturer of the veterinary products.
Table 2. Source and main characteristics of the antimicrobials explored. Both administration patterns and withdrawal periods are recommended by the manufacturer of the veterinary products.
GroupActive
Compound		Commercial
Name		Trading CompanyAdministration
Pattern		Withdrawal
Period (Days)
SulfonamideSulfamethoxypyridazineSULFAMETOXS. P. VETERINARIA (Tarragona, Spain)Attack dose of 40 mg kg−1
Maintenance dose 20 mg kg−1 for 5 days		28
TetracyclineOxytetracyclineALAMYCIN L.A 300KARIZOO LAB (Barcelona, Spain)Single dose of 30 mg kg−128
QuinoloneEnrofloxacinBAYTRILUNO 100 mg mL−1BAYER (Leverkusen, Germany)2 doses of 7.5 mg kg−1 separated 48 h12
Table
Table 3. Monitored ions via LC-MS/MS ESI+ in MRM mode.
Table 3. Monitored ions via LC-MS/MS ESI+ in MRM mode.
CompoundPrecursorProduct1 DP (V)2 CE (V)
Enrofloxacin3603427230
2667250
Ciprofloxacin3323146130
2316150
Ciprofloxacin-D8 (IS)3403226130
Sulfamethoxypyridazine2811566025
1086035
Sulfamethoxypyridazine-D3 (IS)2841566025
Oxytetracycline4614266530
Demeclocycline (IS) 4436517
4651546540
1 DP: declustering potential; 2 CE: collision energy.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Serrano, M.J.; García-Gonzalo, D.; Abilleira, E.; Elorduy, J.; Mitjana, O.; Falceto, M.V.; Laborda, A.; Bonastre, C.; Mata, L.; Condón, S.; et al. Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment. Antibiotics 2021, 10, 762. https://doi.org/10.3390/antibiotics10070762

AMA Style

Serrano MJ, García-Gonzalo D, Abilleira E, Elorduy J, Mitjana O, Falceto MV, Laborda A, Bonastre C, Mata L, Condón S, et al. Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment. Antibiotics. 2021; 10(7):762. https://doi.org/10.3390/antibiotics10070762

Chicago/Turabian Style

Serrano, María Jesús, Diego García-Gonzalo, Eunate Abilleira, Janire Elorduy, Olga Mitjana, María Victoria Falceto, Alicia Laborda, Cristina Bonastre, Luis Mata, Santiago Condón, and et al. 2021. "Antibacterial Residue Excretion via Urine as an Indicator for Therapeutical Treatment Choice and Farm Waste Treatment" Antibiotics 10, no. 7: 762. https://doi.org/10.3390/antibiotics10070762

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop